Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising - Sold 153 million shares at A$0.08 per share

- A$3 million Share Purchase Plan expected to close July 29

MELBOURNE, Australia, July 21, 2014 /PRNewswire/ -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$12.2 million of its A$16.3 million capital raising program. The Company is looking to raise an additional A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.  

Phosphagenics completed the institutional placement for 153,000,000 shares at 8 cents per share on July 11, 2014. Total gross proceeds from this placement to institutions and accredited investors were approximately A$12.2 million. A placement of a further 51,000,000 shares at the same price will be subject to shareholders' approval at a General Meeting to be held on or around August 25, 2014.

Phosphagenics will also seek to raise a further A$3 million through an SPP to existing shareholders at 8 cents per share.  The record date for participating in the SPP offer is July 10, 2014.  The SPP documentation was sent to shareholders on July 17, 2014.

Enquiries

Australia:

David Segal
Investor Relations Manager
Phosphagenics Limited
+61-9565-1103

Rudi Michelson
Monsoon Communications
+61-3-9620-3333

USA:

Matthew Selinger
MZ North America
+1-949-298-4319
mselinger@mzgroup.us

About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM® (Targeted Penetration Matrix).  TPM® is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR -- Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage.  The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria.  Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. 

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development.  Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. 

www.phosphagenics.com
www.bioelixia.com

SOURCE Phosphagenics Limited



RELATED LINKS
http://www.phosphagenics.com
http://www.bioelixia.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.